OS Therapies Completes Herlystic Drug Substance Requalification for Phase 3 Trial

Bitget2026/11/05 13:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OS Therapies completed requalification of Herlystic drug substance used in its Phase 2b osteosarcoma trial, supporting a confirmatory Phase 3 trial.
Reported stability results showed the drug substance retained its critical quality attributes during storage.
The milestone enables submission of a UK conditional marketing application for early commercial access, alongside a Phase 3 trial authorization application.
Manufacturing data delays pushed expected regulatory decisions to the first quarter of 2027 in the UK, versus the first half in Europe.
Recent financing and refundable tax programs provide sufficient resources to fund operations through mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611050800NEWSFILECNPR____20261105_322651_1) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OS Therapies Completes Herlystic Drug Substance Requalification for Phase 3 Trial

You may also like

Crypto prices